Natera (NASDAQ:NTRA – Get Free Report) was upgraded by analysts at Wolfe Research to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.
Several other equities analysts have also recently issued reports on NTRA. Piper Sandler reaffirmed an “overweight” rating and set a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. BTIG Research cut their price target on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. Wells Fargo & Company boosted their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Evercore reissued an “outperform” rating and issued a $270.00 price target on shares of Natera in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.81.
Check Out Our Latest Stock Report on NTRA
Natera Stock Performance
Insider Buying and Selling
In other news, insider John Fesko sold 1,688 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $204.10, for a total value of $344,520.80. Following the completion of the transaction, the insider directly owned 187,511 shares of the company’s stock, valued at $38,270,995.10. The trade was a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 5,838 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32. Following the completion of the transaction, the chief executive officer directly owned 150,769 shares of the company’s stock, valued at approximately $30,777,983.66. This trade represents a 3.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 34,406 shares of company stock valued at $6,984,955. 5.05% of the stock is owned by insiders.
Institutional Investors Weigh In On Natera
Hedge funds and other institutional investors have recently made changes to their positions in the business. Reflection Asset Management purchased a new stake in shares of Natera in the fourth quarter valued at $29,000. Palladiem LLC purchased a new stake in shares of Natera in the fourth quarter valued at $31,000. Bank of Jackson Hole Trust grew its position in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 83 shares during the period. International Assets Investment Management LLC grew its position in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 97 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Natera in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
- Five stocks we like better than Natera
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
